Filter by
Filter by
Initial toxicity, QoL outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated vs. standard fractionated PT for low-risk prostate cancer
A multi-center prospective phase 3 randomized trial aimed to identify differences in toxicity and quality-of-life outcomes between standard fractionation and...
Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes.
A study by the Seattle group analyzed 231 patients of localized prostate cancer treated with protons. Median follow-up was 1.7 years. Grade 3 toxicity was seen...
Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
A retrospective analysis on 100 patients' acute and late genitourinary (GU) and gastrointestinal (GI) toxicities associated with post-prostatectomy proton...
Lymphocyte-Sparing Effect of Proton Therapy in Patients with Esophageal Cancer Treated with Definitive Chemoradiation.
This MD Anderson study compared IMRT and PBT chemoradiation for esophageal cancer. Patients who had IMRT and PBT matched by propensity score (n = 220) were not...